Black Diamond CLAR 深 沪
已收盘 12-12 16:00:00 美东时间
3.38
-0.110
-3.15%
华盛通- 最 高3.54
- 今 开3.52
- 成交量 21.09万股
- 最 低 3.37
- 昨 收 3.49
- 总市值 1.30亿
- 52周最高 4.98
- 市盈率 静 --
- 换手率 0.55%
- 52周最低 2.97
- 委 比 -70.48%
- 总股本 3840.18万
- 历史最高 31.91
- 量 比 1.50
- 振 幅 4.87%
- 历史最低 2.97
- 每 手 1
- 风险率 0.51%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Guggenheim Downgrades Black Diamond Therapeutic to Neutral
Guggenheim analyst Brad Canino downgrades Black Diamond Therapeutic (NASDAQ:BDTX) from Buy to Neutral.
12-04 21:48
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update
Black Diamond Therapeutics will host a webcast on December 3, 2025, at 8:00am ET to present Phase 2 clinical trial results of silevertinib and provide a program update. The webcast will be accessible via the Investors section of their website, www.blackdiamondtherapeutics.com, with a replay available afterward.
12-02 21:01
Piper Sandler Assumes Black Diamond Therapeutic at Overweight, Announces Price Target of $9
Piper Sandler analyst Kelsey Goodwin assumes Black Diamond Therapeutic (NASDAQ:BDTX) with a Overweight rating and announces Price Target of $9.
11-19 01:15
Black Diamond Therapeutic Q3 EPS $(0.15) Beats $(0.23) Estimate
Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.23) by 35.9 percent. This is a 46.43 percent increase over losses of $(0.28) per
11-06 20:35
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Black Diamond Therapeutics reported financial results for Q3 2025, highlighting $135.5 million in cash, sufficient for operations into Q4 2027. The company plans to disclose ORR and preliminary duration data for silevertinib in 1L EGFRm NSCLC later this quarter. R&D expenses decreased to $7.4 million, and net loss was $8.5 million. Black Diamond is seeking partnerships and FDA feedback for silevertinib's development.
11-06 12:30
Clarus declares $0.025 dividend
Clarus (CLAR) declares $0.025/share quarterly dividend, in line with previous. Forward yield 2.92% Payable Nov. 26; for shareholders of record Nov. 17; ex-div Nov. 17. See CLAR Dividend Scorecard, Yie...
11-06 06:55
Clarus Announces $0.025 Per Share Quarterly Dividend
Clarus Corporation announced a quarterly cash dividend of $0.025 per share, payable on November 26, 2025, to stockholders of record as of November 17, 2025. Headquartered in Salt Lake City, Utah, Clarus is a global leader in outdoor equipment and lifestyle products, with brands including Black Diamond®, Rhino-Rack®, MAXTRAX®, TRED Outdoors®, and RockyMounts®.
11-05 21:15
Immunovia’s PancreaSure Test Validated in Leading Journal
Immunovia AB ( ($SE:IMMNOV) ) has provided an announcement. Immunovia announced...
10-27 21:32
CLEAR and Wellstar Health System Modernize the Patient Experience Using CLEAR1’s Digital Check-In
CLEAR and Wellstar expand CLEAR1 identity technology to over 150 locations, enhancing patient check-in efficiency. The partnership streamlines processes, reduces administrative burdens, and cuts costs, with clear success metrics including increased patient satisfaction and significant operational savings.
10-20 20:30
